Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
Clinical trial NCT02601313 · COMPLETED
Trial details
- NCT number
- NCT02601313
- Sponsor
- Kite, A Gilead Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-09
- Primary completion
- 2023-09-22
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.